Sanofi (SNY,SAN.PA) reported that its first quarter net income from continuing operations declined to 1.59 billion euros from 1.72 billion euros, prior year. Basic earnings per share from continuing operations was 1.32 euros compared to 1.39 euros. Business net income was 2.26 billion euros compared to 2.21 billion euros. Business earnings per share increased to 1.88 euros from 1.79 euros.
First quarter net sales were 10.51 billion euros compared to 9.89 billion euros, prior year. At actual exchange rates, sales increased by 6.2%. Dupixent sales increased by 30.8% to 4.2 billion euros.
Olivier Charmeil, interim CEO, said: "We had a strong start to 2026 with double-digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions."
Sanofi reiterated guidance for 2026. The company continues to expect sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, at constant exchange rates, delivering profitable growth.
At last close, shares of Sanofi were trading at 80.78 euros, down 0.30%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.